期刊文献+

慢性肾功能不全对房颤患者使用华法林的影响 被引量:4

Influence of chronic renal failure on usage of warfarin in patients with atrial fibrillation
下载PDF
导出
摘要 目的探讨慢性肾功能不全对阵发性房颤患者使用华法林的影响。方法选择确诊的103例阵发性房颤患者,按是否合并慢性肾功能不全分为两组:观察组(伴有肾功能不全)和对照组(无肾功能不全),两组均使用华法林辅助抗凝治疗。比较华法林治疗后两组患者的国际标准化比值(INR)、出血事件发生率、脑卒中发生人数和华法林相关肾病发生率。结果观察组的INR值为2.71±0.79,对照组的INR值为2.24±0.82,观察组INR值高于对照组,差异有统计学意义(t=2.96,P<0.05),观察组INR>2.5的人数多于对照组,差异亦有统计学意义(χ2=9.92,P<0.05)。观察组患者出血、脑卒中和华法林相关肾病发生率均高于对照组,差异均有统计学意义(χ2分别=7.78、6.13、16.32,P均<0.05)。结论房颤伴慢性肾功能不全患者使用华法林治疗后,各种不良反应发生率相比不伴有肾功能不全的患者明显升高,抗凝血作用也增强。 Objective To explore the effect of chronic renal failure on usage of warfarin in patients with atrial fibrillation. Methods A total of 103 patients with clinical confirmed paroxysmal atrial fibrillation were divided into two groups according to whether complicated with chronic renal failure or not. Patients in both groups received anticoagulant therapy through warfarin. The INR,incidence of bleeding evens and warfarin-related nephropathy, stroke were compared. Results The INR value of the observation group was 2.71±0.79 which was significantly higher than the control group that the INR value was 2.24±0.82 (t=2.96,P〈0.05).The number of INR〉2.5 in observation group were more than the control group (X^2=9.92 ,P〈0.05). The incidence of bleeding evens, stroke and warfarin-related nephropathy in observation group were significantly higher than those of the control group (X^2=7.78,6.13,16.32,P〈0.05). Conclusion The incidences of various adverse reactions in patients with atrial fibrillation combined with chronic renal failure received warfarin therapy are significantly higher than those without renal failure as well as the anticoagulant effect.
出处 《全科医学临床与教育》 2015年第2期156-157,共2页 Clinical Education of General Practice
关键词 肾功能不全 房颤 华法林 chronic renal failure atrial fibrillation warfarin
  • 相关文献

参考文献6

  • 1Olshansky B,Sullivan R. Increased prevalence of atrial fibril- lation in the endurance athlete: potential mechanisms and sport specificity[J]. Phys Sportsmed,2014, 42( 1 ) : 45-51.
  • 2Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate[J]. Kidney Int,2011,80(2) : 181-189.
  • 3Giustetto C, Cerrato N, Gribaudo E, et al. Atrial fibrillation in a large population with Brugada electrocardiographic pat- tern:prevalence, management and correlation with progno- sis[J]. Heart Rhythm, 2014, 11 (2) : 259-265.
  • 4Sabzi F,Faraji R. Right atrial thrombosis associated with sagittal sinus thrombosis caused by protein C-S deficiency[J]. Jnma J Nepal Med Assoc,2013, 52(190) : 378-383.
  • 5张源,殷跃辉,梅霞.心房颤动抗凝治疗新进展[J].心血管病学进展,2012,33(6):743-747. 被引量:5
  • 6Bok SK,Lee YJ,Ahn SY. Recurrent cerebral infarction cau- sed by mobile aortic arch thrombus refractory to warfarin therapy[J]. Ann Rehabil Med, 2013, 37(5) : 750-754.

二级参考文献33

  • 1殷跃辉,刘增长,吴近近,代引,苏立,兰先彬,凌智瑜,杨小渝,罗开良.胺碘酮与氯沙坦、培哚普利联合治疗阵发性心房颤动的前瞻、随机开放研究[J].中华心血管病杂志,2006,34(4):299-302. 被引量:72
  • 2Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the Euro- pean Society of Cardiology (ESC) [ J]. Eur Heart J,2010,31:2369-2429.
  • 3Nattel S, Opie LH. Controversies in atrial fibrillation [ J ]. Lancet, 2006,367 : 262-272.
  • 4Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibril- lation: Virchow's triad revisited[J]. Lancet,2009 ,373 :155-166.
  • 5Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: im- plications for management[J]. Circulation, 2011,124(20) :2264-2274.
  • 6Nieuwlaat R, Dinh T, Olsson SB, et al. Should we abandon the common prac- tice of withholding oral anticoagulation in paroxysmal atrial fibrillation [ J ] ? Eur Heart J,2008,29:915.
  • 7Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibril- lation[J]. JAMA ,2001,285:286d--2870.
  • 8Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atriai fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation [ J ]. Chest, 2010,137:263-272.
  • 9Pisters R, Lane DA, Nieuwlaat R, et ah A novel user friendly score ( HAS- BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey[J]. Chest, 2010,138(5) :1093-1100.
  • 10Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotie therapy to pre- vent stroke in patients who have nonvalvular atrial fibrillation [ J ]. Ann Intern Med ,2007,146:857-867.

共引文献4

同被引文献23

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部